Poxel to Report Its 2023 Annual Results by the End of April 2024
Poxel Reports Cash and Revenue for the Full Year 2023
Poxel Provides Corporate Update
Poxel Reports Cash and Revenue for the Third Quarter
Poxel Announces its Participation at Upcoming Investor Conferences
Poxel Announces its Participation at Upcoming Scientific Conference
France’s Poxel still believes that it can blaze a path forward in rare diseases — but before it can convince investors or partners of that, it’s continuing to tighten the purse strings.
Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the second quarter and first half of 2023.
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the upcoming H.C. Wainwright 2nd Annual Kidney Conference, to be held virtually on July 25, 2023.